Metformin, the first line treatment for type 2 diabetes, targets the circadian gene PRKAB1, which encodes for a regulatory subunit of the AMP-activated protein kinase (AMPK), a master regulator of energy metabolism. The gene discussed is PRKAB1; the disease is type 2 diabetes mellitus.